DrugPatentWatch Database Preview
Drugs in Development Information for Danirixin
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Danirixin?
Danirixin is an investigational drug.
There have been 10 clinical trials for Danirixin.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 28th 2017.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, and Chronic Disease. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].
There are two US patents protecting this investigational drug and fifty-seven international patents.
Summary for Danirixin
| US Patents | 2 |
| International Patents | 57 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-04-28) |
| Vendors | 18 |
Recent Clinical Trials for Danirixin
| Title | Sponsor | Phase |
|---|---|---|
| GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects | GlaxoSmithKline | Phase 1 |
| Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD) | GlaxoSmithKline | Phase 2 |
| A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD) | GlaxoSmithKline | Phase 2 |
Clinical Trial Summary for Danirixin
Top disease conditions for Danirixin
Top clinical trial sponsors for Danirixin
US Patents for Danirixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Danirixin | Start Trial | IL-8 receptor antagonists | GlaxoSmithKline, LLC (Philadelphia, PA) | Start Trial |
| Danirixin | Start Trial | Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N'-(3-fluoro-2- -methylphenyl)urea | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Danirixin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Danirixin | Argentina | 060562 | 2026-04-21 | Start Trial |
| Danirixin | Australia | 2007240365 | 2026-04-21 | Start Trial |
| Danirixin | Brazil | PI0710232 | 2026-04-21 | Start Trial |
| Danirixin | Canada | 2650009 | 2026-04-21 | Start Trial |
| Danirixin | Chile | 2007001142 | 2026-04-21 | Start Trial |
| Danirixin | China | 101472477 | 2026-04-21 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
